Alumis and ACELYRIN Revise Merger Agreement for Enhanced Stakeholder Value
Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company, and ACELYRIN, INC. (Nasdaq: SLRN), focused on immunology, have announced an important amendment to their merger agreement. This revised agreement promises an increased ownership stake for stockholders, signaling a robust alignment of interests between the two entities.
Improved Ownership Structure
The latest amendment to the merger agreement now allows ACELYRIN stockholders to receive 0.4814 shares of Alumis common stock for every share they own, elevating their ownership in the combined company to around 48%. This modification reflects a strategic response to market conditions, ensuring that both sets of stockholders see enhanced value in the merger.
Martin Babler, President, and CEO of Alumis, expressed confidence in the amended terms, stating that the revision was made to maximize opportunities for stockholders while enhancing financial flexibility. He emphasized the potential of the merger to bolster the pipeline of late-stage therapeutic assets, which are expected to generate significant clinical advancements.
Strategic Goals and Benefits
Both companies believe that the merger will create a powerful entity capable of realizing the full value of late-stage products. Bruce Cozadd, Chair of ACELYRIN’s Board of Directors, underscored the feedback received from stockholders and how this influenced the revised agreement. The enhanced stake for ACELYRIN shareholders is a testament to the leadership’s commitment to a successful merger, furthering their credibility within the industry.
Key Points from the Amended Agreement
- The merger is designed to unlock significant potential for ACELYRIN stockholders, creating a comprehensive immunology-focused company.
- The strategic partnership provides access to a diversified portfolio of therapeutic candidates poised for clinical advancement.
- ACELYRIN’s Independent Board Committee has diligently reviewed multiple strategic options, leading to the optimization of terms that favor stockholder interest.
- Alumis expects a strong financial position with approx. $737 million projected cash reserves, ensuring the advancement of critical clinical programs well into 2027.
Next Steps Towards Finalization
The amendment to the merger was unanimously supported by both companies’ Boards of Directors. Notably, stockholders holding approximately 62% of Alumis voting shares and 24% of ACELYRIN shares have already entered into support agreements. This broad consensus is vital for progressing with the transaction.
As part of the regulatory prerequisites, Alumis and ACELYRIN plan to submit updated proxy materials to the Securities and Exchange Commission (SEC) soon. Both companies anticipate concluding the merger in the approaching second quarter, pending necessary approvals from their shareholders.
About Alumis and ACELYRIN
Alumis is dedicated to developing innovative therapies that utilize a precision-focused methodology to better the lives of patients suffering from immune-mediated diseases. The company, leveraging its expertise in data analytics, is fostering a pipeline that addresses various immune system disorders, with its lead candidate, ESK-001, targeting diseases such as psoriasis and lupus.
On the other hand, ACELYRIN is committed to delivering breakthrough treatment options to patients, with its flagship program lonigutamab targeting thyroid eye disease. Both companies are poised to significantly impact the immunology landscape through their evolving clinical portfolios.
Frequently Asked Questions
What is the nature of the merger between Alumis and ACELYRIN?
The merger aims to combine resources and clinical portfolios to enhance shareholder value while encountering new therapeutic opportunities in immunology.
What benefits will ACELYRIN shareholders receive from the merger?
ACELYRIN shareholders will now own approximately 48% of the combined company, an increase from the previous agreement, which enhances their stake in future growth.
When is the expected timeline for the merger completion?
The companies expect to finalize the merger in the second quarter of 2025, pending necessary shareholder approvals.
What are Alumis's leading products in development?
Alumis is advancing its product candidate ESK-001 and others in its pipeline aimed at treating immune-mediated diseases.
How does this merger impact the future of both companies?
This merger enhances financial flexibility and offers a stronger clinical pipeline, positioning both companies for better competitive outcomes in the biopharmaceutical sector.
